Quince Therapeutics Inc
QNCX
Company Profile
Business description
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Contact
611 Gateway Boulevard
Suite 273
South San FranciscoCA94080
USAT: +1 415 910-5717
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
38
Stocks News & Analysis
stocks
Pure-play data center share raises capital to fund AI demand
Funding the next wave of data center growth.
stocks
Chart of the Week: BHP’s growth story faces a reality check
China’s slowing economy could weigh on BHP’s future growth.
stocks
3 best ASX growth stocks to buy for the long term
Here’s three high-quality growth companies with wide moats.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,978.80 | 34.20 | -0.38% |
| CAC 40 | 8,309.17 | 68.69 | -0.82% |
| DAX 40 | 24,717.36 | 198.13 | -0.80% |
| Dow JONES (US) | 52,552.97 | 105.67 | -0.20% |
| FTSE 100 | 10,570.37 | 1.87 | -0.02% |
| HKSE | 24,562.24 | 446.36 | -1.78% |
| NASDAQ | 25,881.95 | 387.28 | -1.47% |
| Nikkei 225 | 64,141.12 | 2,694.42 | -4.03% |
| NZX 50 Index | 13,694.68 | 79.90 | 0.59% |
| S&P 500 | 7,533.77 | 38.63 | -0.51% |
| S&P/ASX 200 | 8,796.70 | 20.10 | -0.23% |
| SSE Composite Index | 3,764.15 | 118.26 | -3.05% |